CiVi Biopharma Takes $40M
San Francisco-based biopharmaceuticals developer CiVi Biopharma, a biopharmaceuticals firm which is targeting cardiometabolic diseases, has raised $40M in a funding round, the company said on Friday. The investment came from Boxer Capital of the Tavistock Group. The funds go towards completion of completion of pre-clinical and early phase I clinical development of its lead compound.
posted on Monday, January 9, 2017 (Link to more information)
Related companies:
CiVi Biopharma
Related stories:
> Alios Biopharma Raises $32M
> Alios BioPharma Lands $41M In Series B
> Limerick BioPharma Gains $15M
> SutroVax Finds $22M
> Principia Biopharma Raises $50M
silicontap.com Home